Skip to content
Radio Logo
PodcastsNatural SciencesThe Genetics Podcast

The Genetics Podcast

Sano Genetics
Latest episode

266 episodes

  • The Genetics Podcast

    EP 266: How patient communities are accelerating rare disease research with Tania Simoncelli of Biohub

    19/11/2026 | 47 mins.
    This week on The Genetics Podcast, Patrick is joined by Tania Simoncelli, Vice President of Translational Impact and Engagement at Biohub. They discuss how patient-led organizations drive rare disease research, the capacity building and partnerships behind the Rare As One network, how AI could change drug repurposing and clinical trials, and Tania’s role in the ACLU case against human gene patents.
    Show Notes
    0:00 Intro to The Genetics Podcast
    00:59 Welcome to Tania
    01:41 The founding story and aim of the Rare As One Project
    05:17 Impact and scale of the Rare As One network, from funding to clinical trials
    10:45 Why cycle four focuses on rare respiratory, immune dysregulation and sarcoma communities
    14:54 How rare disease data and patient networks connect to Biohub’s virtual cell and AI models 
    19:00 The Rare As One partnership with Every Cure on AI-driven drug repurposing 
    24:29 Rare As One partnerships with the Broad Institute, Citizen Health and the Fowler lab
    28:49 Organizational and scientific capacity building for patient-led rare disease organizations
    34:03 Tania’s ACLU case against human gene patents and its impact 
    43:26 How patient communities are adopting AI and where it could take rare disease research
    46:33 Closing remarks
  • The Genetics Podcast

    EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp

    12/11/2026 | 42 mins.
    This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.
    Show Notes
    0:00 Intro to The Genetics Podcast
    00:58 Welcome to Joe 
    01:47 Joe’s career in HIV genetics and his move into neurology
    06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau217
    11:04 Why p-tau217 works as a scalable Alzheimer’s blood test
    12:35 How p-tau217 triages patients and what it can’t tell clinicians
    14:08 APOE testing demand and why it predicts risk without being definitive
    17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown
    21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took
    24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers
    27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau217
    29:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for
    34:27 How Labcorp decides which neurology biomarkers to launch and when
    38:12 Future potential for migraine biomarkers that can guide treatment choices
    41:07 Closing remarks
  • The Genetics Podcast

    EP 264: What AI’s math breakthroughs mean for drug development and genetics

    05/11/2026 | 41 mins.
    This week on The Genetics Podcast, Patrick goes solo to look at what recent AI breakthroughs in mathematics could mean for biology. He discusses the OpenAI results on the Navier-Stokes equation and hundreds of open math problems, what makes math and code so easy for AI to improve on, how self-driving labs and surrogate endpoints could speed up drug development, and where the biggest gaps and opportunities remain.
    Show Notes
    0:00 Intro to The Genetics Podcast
    00:58 What the OpenAI math breakthroughs could mean for biology
    02:57 AI’s recent frontier math results and how mathematicians reacted
    09:12 Lean as a proof checker and why it matters for math
    10:44 Four conditions behind AI’s math progress and how biology compares
    16:22 Why verification speed decides where AI can accelerate biology
    19:35 How lab automation shortens feedback loops for variants and antibodies
    23:13 How validated biomarkers let early trials predict clinical outcomes
    26:11 Why validated surrogate endpoints could speed up drug development
    31:58 How startups and big pharma are building self-driving labs
    33:40 Virtual cell models built from perturbation data
    34:50 Genetics-driven drug discovery and the Phase II success rate question
    37:42 Verification speed and surrogate endpoints as biology’s biggest gaps
    40:38 Closing remarks
  • The Genetics Podcast

    EP 263: Bringing the first cardiovascular gene editing therapy to patients with Sek Kathiresan of Eli Lilly

    29/10/2026 | 36 mins.
    This week on The Genetics Podcast, Patrick is joined by Dr. Sek Kathiresan, CEO of Verve Therapeutics and SVP, Head of Obesity Research and Early Development at Eli Lilly. They discuss how protective genetic variants led to the development of a one-time gene editing therapy for heart disease in the face of early doubt, the phase one results for Verve-102, what recent trial failures mean for genetic target validation, and the unmet needs in obesity treatment.
    Show Notes
    0:00 Intro to The Genetics Podcast
    00:59 Welcome to Sek 
    01:40 Sek’s family history of heart disease and how it motivated him to pursue cardio therapeutics
    03:29 Sek’s background and research on the genetics of coronary artery disease and protective mutations
    08:03 Reactions to the Verve launch and the biological, technological, regulatory, and commercial risks
    11:00 Verve-102 phase one results and the case for lifelong LDL lowering
    16:14 Why cumulative exposure means lowering LDL earlier and for longer
    17:53 Recent trial failures in genetically validated targets and what the Lp(a) trial leaves unanswered
    20:33 Polygenic risk scores and who benefits most from LDL lowering
    23:36 Sek’s new role at Lilly and the remaining unmet needs in obesity treatment
    29:06 Whether one-time gene therapy could work for obesity and how GLP-1 drugs drive weight loss
    30:38 Food intake, energy expenditure, and the search for new obesity mechanisms
    32:15 Why Lilly is investing so heavily in genetic medicine
    34:35 Closing remarks
    Find out more
    ANGPTL3 study in NEJM (https://pmc.ncbi.nlm.nih.gov/articles/PMC3008575/)

    Verve-102 study (https://www.nejm.org/doi/10.1056/NEJMoa2601283)
  • The Genetics Podcast

    EP 262: The genetic drivers of hemochromatosis, drug response, and multimorbidity with Luke Pilling of the University of Exeter

    22/10/2026 | 38 mins.
    This week on The Genetics Podcast, Patrick is joined by Dr. Luke Pilling, Senior Lecturer in Genetic Epidemiology at the University of Exeter. They discuss hemochromatosis and the case for earlier diagnosis, and the genetic drivers of multimorbidity, pharmacogenetics, and drug response.
    Show Notes
    0:00 Intro to The Genetics Podcast
    00:59 Welcome to Luke 
    01:37 An overview of HFE hemochromatosis and why diagnosis is delayed 
    04:24 Iron levels and overload risk in heterozygous and compound heterozygous carriers
    05:51 Aging-related effects seen in homozygotes 
    06:43 How hemochromatosis is currently diagnosed and detected in the UK
    09:26 Future screening and case finding, including the Our Future Health cohort
    11:28 Genetic and environmental factors that shape outcomes in C282Y homozygotes 
    13:28 The GEMINI project and the genetic drivers of multimorbidity
    15:56 Drug targets from multimorbidity genetics, including repurposing and opposite effects
    18:49 Using disease sequences in health records to look for earlier intervention points in multimorbidity
    21:21 Data gaps limiting multimorbidity research, from primary care records to proteomics
    23:17 Handling misdiagnosis and clinical code accuracy in health record research
    24:55 International collaborations and the need for more diverse biobank data
    26:08 Pharmacogenetics research and how genetic variants shape drug response
    29:04 Limited clinical examples of pharmacogenetics and lessons from non-responders
    33:08 Genetics of lifespan and healthy aging, and why geroscience pathways rarely appear in GWAS
    36:06 Luke’s future research focuses 
    40:39 Closing remarks
    Find out more:
    - Hereditary hemochromatosis study
    - Multimorbidity study
    - Pharmacogenetics framework study
More Natural Sciences podcasts
About The Genetics Podcast
Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research. To find out more about Sano Genetics and its mission to accelerate the future of precision medicine visit: www.sanogenetics.com
Podcast website

Listen to The Genetics Podcast, The Common Descent Podcast and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features